rts logo

Is TG Therapeutics Inc (TGTX) a good stock to buy now?

TG Therapeutics Inc (NASDAQ: TGTX) is -15.46% lower on its value in year-to-date trading and has touched a low of $6.46 and a high of $35.67 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The TGTX stock was last observed hovering at around $14.77 in the last trading session, with the day’s loss setting it -0.33%.

Currently trading at $14.44, the stock is -9.93% and -6.99% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.77 million and changing -2.23% at the moment leaves the stock -0.08% off its SMA200. TGTX registered -1.30% loss for a year compared to 6-month gain of 72.73%. The firm has a 50-day simple moving average (SMA 50) of $9.09 and a 200-day simple moving average (SMA200) of $81.35.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

The stock witnessed a -19.60% loss in the last 1 month and extending the period to 3 months gives it a -15.46%, and is -7.97% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.70% over the week and 4.57% over the month.

TG Therapeutics Inc (TGTX) has around 264 employees, a market worth around $2.23B and $233.66M in sales. Current P/E ratio is 1024.11 and Fwd P/E is 32.40. Profit margin for the company is 5.42%. Distance from 52-week low is 123.53% and -59.52% from its 52-week high. The company has generated returns on investments over the last 12 months (4.70%).

TG Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -$0.04 with sales reaching $54.58M over the same period.The EPS is expected to shrink by -261.11% this year, but quarterly earnings will post 12.90% year-over-year. Quarterly sales are estimated to grow 599.50% in year-over-year returns.

TG Therapeutics Inc (TGTX) Top Institutional Holders

301 institutions hold shares in TG Therapeutics Inc (TGTX), with institutional investors hold 65.25% of the company’s shares. The shares outstanding are 151.42M, and float is at 139.36M with Short Float at 24.53%. Institutions hold 59.33% of the Float.

The top institutional shareholder in the company is Vanguard Group Inc with over 13.46 million shares valued at $334.22 million. The investor’s holdings represent 8.91% of the TGTX Shares outstanding. As of Jun 29, 2023, the second largest holder is Blackrock Inc. with 9.92 million shares valued at $246.35 million to account for 6.57% of the shares outstanding. The other top investors are Darwin Global Management, Ltd. which holds 9.28 million shares representing 6.15% and valued at over $230.48 million, while FMR, LLC holds 4.03% of the shares totaling 6.08 million with a market value of $151.05 million.

TG Therapeutics Inc (TGTX) Insider Activity

The most recent transaction is an insider sale by Lonial Sagar,the company’sDirector. SEC filings show that Lonial Sagar sold 5,000 shares of the company’s common stock on Mar 13 ’24 at a price of $15.94 per share for a total of $79675.0. Following the sale, the insider now owns 0.11 million shares.

TG Therapeutics Inc disclosed in a document filed with the SEC on Mar 12 ’24 that Charney Laurence N (Director) sold a total of 22,000 shares of the company’s common stock. The trade occurred on Mar 12 ’24 and was made at $15.97 per share for $0.35 million. Following the transaction, the insider now directly holds 0.22 million shares of the TGTX stock.

Still, SEC filings show that on Jan 05 ’24, Charney Laurence N (Director) disposed off 17,500 shares at an average price of $19.03 for $0.33 million. The insider now directly holds 237,229 shares of TG Therapeutics Inc (TGTX).

Related Posts